How provider organizations engage with the Electrome platform across the access, clinical, and outcomes program lines.
Provider organizations engage with the Electrome platform through three program lines that are designed to fit different organizational starting points. The access program supports organizations that want to serve a defined cohort with a non opioid option without restructuring the rest of their pain care. The clinical program supports organizations that are building a multimodal pain program and want bioelectric therapy as one of the modalities. The outcomes program supports organizations that have an existing program and want to add the bioelectric platform as a longitudinal data layer.
The access program is the lightest weight option. The platform supplies the wearable, the patient onboarding, the educational content, and the data backbone. The provider's clinical team identifies the cohort and stays in the loop on patient outcomes. The program is intended for organizations whose appetite is to add the option without taking on additional operational complexity, and most early organizations begin here.
The clinical program is for organizations building or expanding a multimodal pain program. The bioelectric therapy is one component, and the platform integrates with the rest of the program's documentation and quality measurement infrastructure. RTM workflows are operationalized inside the program. The clinical workspace becomes a routine part of the team's day.
The outcomes program is for organizations with mature pain programs that want to add the platform as a longitudinal data layer. The platform's data backbone slots in alongside the organization's existing reporting, and the bioelectric therapy adds a new dataset that the organization can use to characterize its population's response to non pharmacologic intervention.
The right starting point is a short conversation with the platform team to identify which program fits the organization's posture today, with the understanding that organizations often migrate between program lines as their experience grows. The conversation is not a sales pitch. It is a fit question, and the platform team is comfortable saying that a particular organization is not ready, or that a particular program is not the right fit yet.
How provider organizations engage with the Electrome platform across the access, clinical, and outcomes program lines.
More stories
Provider organizations leading the non opioid shift are not waiting for permission. They are building the programs that the rest of the system will follow.

Bioelectric therapy is not a workflow disruptor. It is a workflow addition that the existing chronic pain program can absorb without restructuring.

The CMS access framework rewards programs that combine evidence based therapy, longitudinal data, and equitable access. The Electrome platform is built to do all three.